Streetbeat News

OPTHF

Optimi Health Corp

https://optimihealth.ca/

Industry

Pharmaceutical Preparation Manufacturing

Open

0.15

Mkt cap

15M

Volume

100

High

0.16

P/E Ratio

-3.89

52-wk high

0.43

Low

0.15

Div yield

N/A

52-wk low

0.12

Psyence Biomedical Ltd. (NASDAQ:PBM) is advancing its psychedelic-based mental health solutions with a Phase IIb trial in Australia and the acquisition of Clairvoyant. The company is also partnering with Optimi Health (OTC:OPTHF) for psilocybin supply, aiming for significant data readouts in 2025.

Portfolio Pulse from Juan Spínelli

September 16, 2024 | 5:42 pm

Optimi Health Corp. (OTC:OPTHF) has received a license to export psilocybin and MDMA to Australia, marking a significant milestone in the medical psychedelic drugs market. The company aims to become a key player in the manufacture of pharmaceutical-grade psychedelics. Despite regulatory challenges in the U.S., Optimi is positioning itself for global market leadership.

Portfolio Pulse from Rolando García

June 06, 2024 | 1:12 am

The article provides a comprehensive roundup of recent developments in the psychedelics field, including research findings, global regulatory perspectives, therapeutic applications, and business news. Key highlights include potential roles of psilocybin in dementia prevention and psychological flexibility, global legalization trends, and various companies' strategic moves such as voluntary delistings, partnership agreements, financial results, and patent filings related to psychedelic therapies.

Portfolio Pulse from Lara Goldstein

April 17, 2024 | 1:13 pm

Optimi Health Corp. (OTCQX:OPTHF), a Canadian psychedelics pharmaceutical manufacturer, has entered into an agreement to supply natural psilocybin to New Zealand's Mātai Medical Research Institute for the Tū Wairua Project. This marks Optimi's first supply deal in New Zealand, contributing to its global expansion. The company will provide GMP Full Spectrum Natural Psilocybin extract for a pilot study aimed at evaluating psychedelic-assisted therapy for Māori patients. The study, set for mid-2024, will integrate Māori cultural practices and aims to inform future trials for methamphetamine use disorder among Māori patients.

Portfolio Pulse from Lara Goldstein

April 09, 2024 | 7:26 pm

PharmAla Biotech (MDXXF) and Numinus Wellness (NUMIF) have entered into a sales agreement for MDMA supply for clinical trials in Canada. Similarly, Optimi Health (OPTHF) has partnered with Tel Aviv University for MDMA research on addiction. These deals mark significant advancements in MDMA-assisted psychotherapy and addiction research, with potential impacts on mental health treatment practices.

Portfolio Pulse from Lara Goldstein

March 26, 2024 | 7:35 pm

The Usona Institute has shared positive results from its Phase 2 trial assessing a single 25mg synthetic psilocybin dose for adults with Major Depressive Disorder. COMPASS Pathways (NASDAQ:CMPS) has also shared results from research on its novel AI technologies to support proprietary COMP360 psilocybin treatment for Treatment-Resistant Depression. In the UK, drug policy reform is underway, with a report urging the reclassification of psilocybin mushrooms and other psychedelics to Schedule 2. Several US states are also moving reform bills concerning the study or legalization of psychedelic substances for therapeutic purposes. The AdvisorShares Psychedelics ETF (NYSE:PSIL) opened at $1.79 on September 5, recovering from the prior week’s $1.65.

Portfolio Pulse from Lara Goldstein

September 11, 2023 | 1:34 pm

Optimi Health (OTCQX:OPTHF) has received approval from Health Canada to supply MDMA and psilocybin drugs to the country's Special Access Program (SAP). The company has also secured CA$1M in private financing through a non-dilutive debt financing agreement. The loan, bearing a 7.5% annual interest rate, is secured against the company's assets and will be fully repaid by August 29, 2026.

Portfolio Pulse from Lara Goldstein

September 08, 2023 | 3:15 pm

The American Psychedelic Practitioners Association and BrainFutures have published the first-ever professional practice guidelines for psychedelic-assisted therapy. Algernon NeuroScience, a subsidiary of Algernon Pharmaceuticals, has finalized its clinical trial design for a phase 2 DMT stroke study. Atai Life Sciences, MindMed, and COMPASS Pathways have reported their Q2 2023 financial results. AdvisorShares Psychedelics ETF has seen a decrease in its weekly performance.

Portfolio Pulse from Lara Goldstein

August 14, 2023 | 1:47 pm

Optimi Health Corp. (OTCQX:OPTHF) has completed its proprietary natural psilocybin extraction process and filed a U.S. provisional patent application. Red Light Holland Corp. (OTCQB:TRUFF) received approval to further manufacturing plans for natural psilocybin microdosing capsules. MGC Pharmaceuticals Ltd (OTC:MGCLF) has gained approval for its first import of psilocybin mushrooms to Slovenia for research purposes.

Portfolio Pulse from Lara Goldstein

August 04, 2023 | 10:37 am

A bipartisan bill has created a $75 million research grant program for the potential treatment of mental health conditions in active duty military members. The Multidisciplinary Association for Psychedelic Studies (MAPS) announced its final agenda for its upcoming event, which will include information on two recently-identified lead compounds. Psychedelics were featured on Anderson Cooper’s CNN show. Several companies, including Silo Pharma, Clearmind, and SciSparc, are developing treatments using psychedelics. The AdvisorShares Psychedelics ETF (PSIL) showed an uptrend.

Portfolio Pulse from Lara Goldstein

July 03, 2023 | 9:01 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.